No abstract

Compared to the Non-PG, the PG was younger (p ¼ 0.014), had higher pain scores at their index visit (median 8.5, quartile 5.5, 10, p ¼ 0.0002) with a little over half achieving a MCSD in their index visit pain scores (57%). In the PG, 61% (45) reported home opioid use at the index visit and 31% (14) received another opioid prescription. Of the 17 in the PG discharged with an opioid (23%), 13 returned for worsening symptoms and 4 for medication issues. Compared to the PG, more patients in the Non-PG were admitted (74%, p ¼ 0.018), had low REALM scores (75%, p ¼ 0.005), and presented with a respiratory chief complaint at their index visit (p ¼ 0.004). Socioeconomic disadvantage, sex, ethnicity, index visit mode of arrival, and insurance type was not significantly different between groups. As continuous variables, age (p ¼ 0.016), index visit pain scores (p ¼ <0.001), and index visit acuity (p ¼ 0.028) were significantly different between groups. Age (OR 0.9, 95% CI 0.8-0.9, p ¼ 0.047), REALM scores (OR 3.1, 95% CI 1.3 -7.5, p ¼ 0.011), and index visit pain scores (OR 1.1, 95% CI 1.0-1.2, p ¼ 0.004) were predictive of ED returns for pain in older adults.Conclusions: The likelihood of returns for pain in older adults decreased with age; increased with higher REALM scores; and increased by 10% for each point increase in pain scores.

Introduction: Resuscitation medication shortages are widespread across the US. We sought to determine the frequency and quantity of meds used during IHCA. Methods: Retrospective, single center, chart review at a large, urban teaching hospital. Adults over 18 who suffered IHCA between Jan 2017 and Mar 2018 were identified. Trained and supervised research assistants used a standardized data tool to extract data from the EMR. Primary outcome was the frequency and quantity of ACLS meds used during IHCA. Secondary outcomes included evaluating the association of med administration with ROSC and survival as well as the use of sodium bicarb with survival in patients with pre-existing end stage renal disease. Results: Criteria were met for 181 IHCA events. Demographics: 71% (128 of 181) black; mean age 65; and 46% (83 of 181) women. Epi was given in 86.7% (157 of 181) cases, with average cumulative dose of 4.2 mg, sodium bicarb given in 63.5% (115 of 181), average dose of 1.9 amps, calcium chloride given in 39.2% (71 of 181), average dose of 1.9 amps, amiodarone was given in 30.9% (56 of 181), average dose of 311.8 mg, and atropine was given in 13.8% (25 of 181), average dose of 1.3 amps. Administration of sodium bicarb was associated with lower rates of ROSC (OR 0.31, 95% CI 0.18 to 0.83) and lower survival (OR 0.31, 95% CI 0.13 to 0.73). Administration of mag sulfate was associated with lower rates of ROSC (OR 0.33, 95% CI 0.13 to 0.83), but no difference in survival (OR 0.34, 95% CI 0.10 to 1.14). Administration of epi, amiodarone, calcium, dextrose, or atropine was not associated with a change in rates of ROSC or survival. In patients with pre-existing ESRD (45 of 181), 73.3% (33 of 45) received sodium bicarb, with 51.5% (17 of 33) achieving ROSC, and 12.1% (4 of 33) surviving to discharge. In patients without ESRD (136 of 181), 60.3% (82 of 136) received sodium bicarb, with 65.9% (54/82) achieving ROSC, and 22.0% (18 of 82) surviving to discharge. (12.1% vs 22.0% p = 0.224). Conclusions: Substantial amounts of drugs with known recent shortage are used in IHCA with no significant increase in ROSC or survival to discharge. Administration of sodium bicarb during IHCA is associated with lower rates of ROSC and survival. These results may be due to confounders such as code duration.

Study Objectives: Every year 33,000 people suffer an IHCA with an initial shockable rhythm in the US. Rapid Response Teams may increase time to defibrillation and are not associated with lower in-hospital mortality. We sought to describe characteristics of sudden IHCAs with a shockable initial rhythm in a system with mature Rapid Response and Code Blue teams, in particular, time to defibrillation. Methods: Retrospective chart review at a large, urban teaching hospital with mature Rapid Response and Code Blue teams. Adults in whom a “Code Blue” was called with confirmed cardiac arrest between Jan 2017 and Mar 2018 were included. Codes with incomplete data or that occurred in the ED or ICU were excluded. The “Code Blue” team consists of 1-3 Nurse Responders, a nursing supervisor, a respiratory therapist, Anesthesiology, a critical care resident, and a surgical resident. Each ward has a defibrillator and standardized code cart. Trained and supervised research assistants used a standardized data collection tool to extract demographic information, comorbidities and event related data from code sheets, history and physical, progress notes, discharge and death summaries. Events were categorized by initial rhythm as shockable or non-shockable. Time to defibrillation was defined as the interval from reported time of initial recognition of cardiac arrest to the reported time of first attempted defibrillation. Fisher’s exact testing was used to test for statistical significance. Results: A total of 183 “Code Blues” met criteria. Demographics: 71% black; mean age 65; and 46% women. Fifty-five (30%) survived to hospital discharge. Forty (21.3%) had an initial shockable rhythm of whom 21 (52.5%) survived to hospital discharge. Of the 40 patients that had an initial shockable rhythm, 36 were defibrillated. Median time to defibrillation was 2 minutes [IQR = 1-4]. Of those defibrillated within 2 minutes, survival was 64% vs 33% (P = 0.102) among those defibrillated in > 2 minutes. Of the 143 patients that had a nonshockable initial rhythm, 34 (23.8%) survived to hospital discharge. Conclusion: In a system with mature Rapid Response and Code Blue teams, time to defibrillation among IHCA patients with a shockable initial rhythm is 2 minutes.

Multisystem inflammatory syndrome in children is an emerging pediatric illness associated with severe acute respiratory syndrome coronavirus 2 infection. The syndrome is rare, and evidence-based guidelines are lacking. This report reviews a patient who presented for medical care multiple times early in the course of his illness, thus offering near-daily documentation of symptoms and laboratory abnormalities. The patient did not have thrombocytopenia, anemia, or myocardial inflammation until the fifth day of fever. These laboratory abnormalities coincided with the onset of rash, conjunctival injection, vomiting, and diarrhea: clinical signs that could serve as indicators for when to obtain blood tests. The timing of this patient’s onset of multisystem involvement suggests that testing for multisystem inflammatory syndrome in children after only 24 h of fever, as the Centers for Disease Control and Prevention recommends, may yield false-negative results. Testing for multisystem inflammatory syndrome in children after 4 days of fever may be more reliable.